An undisclosed corporate investor has led the first close of a $77m series D round for US-based medical device maker Ablative Solutions with investment firm Glide Healthcare and venture capital partnership BioStar Ventures.
The round also featured Novus Biotechnology, a life sciences-focused vehicle run by private equity fund manager Open Prairie, as well as investment partnership Michigan Accelerator Fund and several private investors.
Ablative is developing a medical device known as Peregrine System that is intended to treat patients with conditions such as high blood pressure, heart failure, kidney disease and sleep apnoea by delivering small doses of dehydrated alcohol to their nerves.
Proceeds from the series D round will be used to complete clinical trials of the product. It would increase the company’s overall equity funding to approximately $120m altogether, according to press releases and regulatory filings.
BioStar Ventures and Michigan Accelerator Fund co-led Ablative’s $5.3m series A round in 2012 and its a $9.5m series B two years later, the latter of which included the conversion of debt financing that had been raised in 2013.
The company added $14.5m in January 2015 and a further $2.4m in November the same year, before raising $11.4m in early 2017, according to securities filings.